More like this
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United StatesSupreme Court of the United States
CONFIRMED84% CONFIDENCE134 days agoThe order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".[1]The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.0.80Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United StatesUnited States Court of Appeals for the Fifth Circuit
CONFIRMED83% CONFIDENCE16 days agoThe court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".[1]A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.0.78Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance
Supreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
CONFIRMED84% CONFIDENCE2.3 years agoThe slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".[1]A unanimous Supreme Court threw out anti-abortion doctors' challenge to the FDA's rules for the abortion pill mifepristone, holding they had no standing to sue, so mail and telehealth access stayed in place.0.74FDA Approves Evita Solutions' Generic Mifepristone
Mahan Court, Federal Research Center, White Oak, Montgomery County, Maryland, 20993, United StatesEvita Solutions
CONFIRMED83% CONFIDENCE360 days agoThe ANDA 216616 approval letter says "the ANDA is approved, effective on the date of this letter" and is digitally signed "Date: 9/30/2025 10:20:02AM".[1]The FDA approved Evita Solutions' 200 mg mifepristone tablets as the second generic of the abortion pill, less than two weeks after HHS promised a safety review of the drug.0.68Third Circuit Lists Arm's Appeal Against Qualcomm for October 20
James A. Byrne Courthouse, 601, Market Street, Old City, Center City, Philadelphia, Philadelphia County, Pennsylvania, 19106, United StatesQualcomm
SCHEDULED80% CONFIDENCEin 25 daysThe clerk's letter says the case 'has been tentatively listed on the merits for Tuesday, October 20, 2026, in PHILADELPHIA, PA' and may move 'to another day within the week of October 19, 2026'.[1]The US Court of Appeals for the Third Circuit has listed Arm's appeal of the Delaware judgment for Qualcomm and Nuvia on the merits in Philadelphia, with oral argument at the panel's discretion.0.65Federal Circuit Hears ParkerVision's Appeal in Qualcomm Patent Case
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United States
CONFIRMED89% CONFIDENCE116 days agoThe Federal Circuit's notice says 'This case has been scheduled for oral argument on June 1, 2026 at 10:00 a.m.', and the court posted the argument's audio on 1 June 2026.[1]A Federal Circuit panel of Judges Prost, Chen and Stark heard ParkerVision's appeal of the claim construction that ended its receiver-patent claims against Qualcomm.0.64FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
Mahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United StatesRoche
SCHEDULED78% CONFIDENCEin 66 daysRoche's[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.0.63FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
CONFIRMED87% CONFIDENCE31 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.0.63Arm Appeals Its Loss to Qualcomm to the Third Circuit
J. Caleb Boggs Federal Building, 844, North King Street, Downtown, Wilmington, New Castle County, Delaware, 19801, United StatesArm Holdings
CONFIRMED89% CONFIDENCE359 days agoArm's notice of appeal is filed 10/01/25 and signed 'Dated: October 1, 2025'.[1]Arm filed a notice of appeal to the US Court of Appeals for the Third Circuit a day after a Delaware judge entered final judgment for Qualcomm and Nuvia in its licence suit.0.63Abbott Settles DOJ Infant Formula Claims for $385 Million
CONFIRMED88% CONFIDENCE11 days agoThe release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.[1]Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.$385M0.62Florida Court Enters Judgment for Qualcomm on ParkerVision Receiver Claims
401, West Central Boulevard, Callahan, Orlando, Orange County, Florida, 32801, United States
CONFIRMED86% CONFIDENCE358 days agoThe order granting the stipulated Rule 54(b) final judgment is 'Signed by Judge Paul G. Byron on 10/2/2025'; Qualcomm's 10-K says 'On October 2, 2025, the court entered a final judgment in our favor'.[1]Eleven years into ParkerVision's radio-chip patent suit, a federal judge in Orlando entered a stipulated final judgment that Qualcomm does not infringe its receiver patents and stayed the rest pending appeal.0.62Lilly Submits Retatrutide to the FDA for Approval
Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly
ESTIMATED3 months late77% CONFIDENCEin 187 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.[1]Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.0.62
